Articles on osteoporosis drugs from NPS RADARArticles on osteoporosis drugs from NPS RADAR

Title Content Type Date Description
Denosumab (Prolia) for postmenopausal osteoporosis Professional publication - NPS RADAR - Review 2010-12-01 00:00:00 Denosumab (Prolia) is the first monoclonal antibody listed for postmenopausal osteoporosis. Its effect on fracture rates compared with that of other anti-resorptive therapies is not known, and more data are required to characterise denosumab’s long-term safety profile.
Alendronate and its combinations: PBS listing extended to corticosteroid-induced osteoporosis Professional publication - NPS RADAR - Brief item 2010-11-09 00:00:00 Alendronate and its combinations with calcium and/or cholecalciferol may be prescribed on the PBS for treating people who are currently receiving long-term high-dose corticosteroid therapy and have low bone mineral density.
Strontium ranelate (Protos) for postmenopausal osteoporosis Professional publication - NPS RADAR - Web only item 2010-04-23 00:00:00 New information relevant to this topic has become available since this RADAR review was published in November 2007.
Extended PBS listings for zoledronic acid 5mg (Aclasta) Professional publication - NPS RADAR - Brief item 2010-04-01 00:00:00 From 1 April 2010 zoledronic acid can be prescribed for men with osteoporosis with or without fracture, for people with corticosteroid-induced osteoporosis or for people with symptomatic Paget’s disease.
Risedronate (Actonel Once-a-month) and summary of anti-resorptive drug listings Professional publication - NPS RADAR - Brief item 2009-08-01 00:00:00 Risedronate once-monthly tablets are now PBS-listed for the treatment of osteoporosis. A summary of anti-resorptive drug listings for osteoporosis is provided.
Teriparatide (Forteo) for severe osteoporosis Professional publication - NPS RADAR - Review 2009-08-01 00:00:00 Teriparatide is subsidised on the Pharmaceutical Benefits Scheme for severe established osteoporosis in people at very high risk of fracture who develop one or more new symptomatic fractures despite at least 12 months of continuous antiresorptive therapy.
Zoledronic acid (Aclasta) for osteoporosis Professional publication - NPS RADAR - Review 2009-04-01 00:00:00 The PBS listing of zoledronic acid has been extended and now covers osteoporosis in any postmenopausal woman aged 70 years or older who has a bone mineral density (BMD) T-score less than or equal to –3.0. The NPS RADAR review has been updated accordingly.
Risedronate (Actonel and Actonel Once-a-Week) for corticosteroid-induced osteoporosis Professional publication - NPS RADAR - Brief item 2009-02-10 00:00:00 The PBS listing for risedronate (Actonel and Actonel Once-a-Week) and risedronate with calcium (Actonel Combi) has been extended to people with corticosteroid-induced osteoporosis (CIO) who are on long-term high-dose corticosteroid therapy.
Alendronate with cholecalciferol (vitamin D3) (Fosamax Plus) for osteoporosis Professional publication - NPS RADAR - Review 2008-12-01 00:00:00 This new formulation of alendronate with cholecalciferol (vitamin D3) (Fosamax Plus) contains twice the cholecalciferol dose of the previous formulation — 5600 units in a once-weekly dose, equivalent to 800 units/day. The cholecalciferol 2800 unit formulation is gradually being phased out by the manufacturer.
Strontium ranelate (Protos) for postmenopausal osteoporosis Professional publication - NPS RADAR - Review 2007-11-01 00:00:00 Reviews use of strontium ranelate for postmenopausal osteoporosis, with emphasis on reducing risk of fracture.
Risedronate sodium (Actonel) and risedronate sodium with calcium carbonate (Actonel Combi) listing for osteoporosis in patients at high risk of fracture Professional publication - NPS RADAR - Brief item 2007-08-01 00:00:00 The PBS restriction for risedronate was extended o allow the treatment of osteoporosis among patients aged 70 years or older with low bone mineral density scores but without an existing minimal trauma fracture.
Alendronate (Alendro Once Weekly, Fosamax Once Weekly, Fosamax Plus) for osteoporosis in people at high risk of fracture Professional publication - NPS RADAR - Review 2007-02-01 00:00:00 Reviews extension of PBS listing for alendronate to include treatment of osteoporosis without fracture in older people with low bone mineral density scores.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

RSS FeedRSS feed

Date published: 2009-10-28 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.